%0 Journal Article
%T Safety of Landiolol Infusion in Patients  Undergoing Lung Resection
%A Kenji Ito
%A Masahisa Nozaki
%A Reinii Sakamoto
%A Toshiyasu Suzuki
%A Ryota Masuda
%A Masayuki Iwazaki
%J Open Journal of Anesthesiology
%P 183-190
%@ 2164-5558
%D 2014
%I Scientific Research Publishing
%R 10.4236/ojanes.2014.48026
%X <p style=\"text-align:justify;\">
	<span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">The efficacy of landiolol hydrochloride, an ultrashort-acting </span><i><span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">b</span></i><span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">-blocker with high </span><i><span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">b</span></i><span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">1 selectivity, has been
confirmed in patients undergoing cardiac surgery in Japan, but there have been
few reports about its use for patients having lung resection.</span><span style=\"font-size:10.0pt;line-height:97%;font-family:;\" \"=\"\"> </span><span style=\"font-size:10.0pt;line-height:97%;font-family:;\" \"=\"\"><span style=\"font-family:Verdana;line-height:1.5;\">We investigated the safety of continuous infusion of
landiolol in patients undergoing lung resection. Between May 2008 and May 2011,
200 patients </span><span style=\"font-family:Verdana;line-height:1.5;\">scheduled for lung resection
were enrolled. Patients who underwent surgery before the </span><span style=\"font-family:Verdana;line-height:1.5;\">introduction of
landiolol in February 2010 were studied retrospectively (Group C) and were
compared with those who received landiolol along with surgery (Group L). During
the 48-hour study period, the incidence of arrhythmias, changes in heart rate
and blood pressure, and occurrence of adverse reactions were examined. The white
blood cell count and C-reactive protein level were measured before and after
surgery to assess the anti-inflammatory effect. The heart rate was
significantly lower in Group L throughout the study period. No patient in Group
L developed hypotension requiring discontinuation of landiolol therapy, and
no respiratory symptoms (including asthma or hypoxemia) were observed. White
blood cell and C-reactive protein were significantly increased after surgery in
both groups, and there were no between-group differences. Arrhythmic events occurred
in 1.1% (1/99) and 9.2% (7/76) of Group L and Group C, respectively. One
patient in Group C developed ventricular tachycardia. Landiolol can be
administered safely during the perioperative period in patients undergoing lung
resection.</span></span> 
</p>
%K Landiolol
%K Postoperative Arrhythmia
%K Lung Resection
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=48626